C12N 2795/10122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/10122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 75 US grants and 105 published applications in this corpus.
Search patents in C12N- Granted patents
- 75
- Published applications
- 105
- Assignees
- 68
- Inventors
- 229
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 0 | 0 |
| 1999 | 5 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 4 | 2 |
| 2003 | 0 | 7 |
| 2004 | 1 | 3 |
| 2005 | 0 | 3 |
| 2006 | 1 | 1 |
| 2007 | 1 | 2 |
| 2008 | 2 | 3 |
| 2009 | 1 | 1 |
| 2010 | 0 | 2 |
| 2011 | 2 | 2 |
| 2012 | 1 | 1 |
| 2013 | 1 | 3 |
| 2014 | 1 | 5 |
| 2015 | 3 | 4 |
| 2016 | 4 | 5 |
| 2017 | 7 | 8 |
| 2018 | 4 | 4 |
| 2019 | 7 | 4 |
| 2020 | 1 | 7 |
| 2021 | 4 | 7 |
| 2022 | 3 | 12 |
| 2023 | 4 | 5 |
| 2024 | 1 | 5 |
| 2025 | 7 | 6 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Therapeutic bacteriophages22 Sep 2026US 12,742,158 B2University of Leicester
- Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder25 Aug 2026US 12,715,903 B2Palleon Pharmaceuticals Inc.
- Lentiviral-based vectors and related systems and methods for eukaryotic gene editing26 Aug 2025US 12,398,182 B2Wake Forest University Health Sciences
- Respiratory syncytial virus recombinant F protein and vaccine composition containing same1 Jul 2025US 12,344,636 B2SK Bioscience Co., Ltd.
- CRISPR-Cas effector polypeptides and methods of use thereof27 May 2025US 12,312,614 B2The Regents of the University of California
- Bacteriophage(s) targeting capsular deficient klebsiella pneumoniae (kp), compositions comprising it(them) and use(s) thereof3 Sep 2026US 2026/0258374 A1
- Crop treatment16 Jul 2026US 2026/0198510 A1APS Biocontrol Limited
- Compositions and methods for producing circular polyribonucleotides25 Jun 2026US 2026/0176637 A1Flagship Pioneering Innovations VI, LLC
- Bacteria-targeting capsid particle, treatment composition, disinfectant, food, bacteria elimination method, bactericidal method, corrosion prevention method, animal treatment method, gene introduction method, bacteria function addition method, method for producing bacteria-targeting capsid particle, and method for producing nucleic acid for bacteria-targeting capsid particle25 Dec 2025US 2025/0387442 A1Jichi Medical University
- Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof13 Nov 2025US 2025/0345378 A1Locus Biosciences, Inc.
Most cited
By later US patents
- Autocatalytic replication of recombinant RNA181US 4,786,600 AThe Trustees of Columbia University in the City of New York · 1988
- Ribonuclease resistant viral RNA standards180US 5,677,124 AAmbion, Inc. · 1997
- Ribonuclease resistant RNA preparation and utilization80US 5,939,262 AAmbion, Inc. · 1999
- Ribonuclease resistant viral RNA standards43US 5,919,625 AAmbion, Inc. · 1999
- Protein size marker ladder27US 5,449,758 ALife Technologies Corporation · 1995